

- **Name:** Chan-Young Ock
 - **Current Position & Affiliation:** Lunit Inc. / Bang & Ock Consulting Inc.
 - **Country:** Republic of Korea
-

• Educational Background:

- 2002.3-2008.2 Seoul National University, College of Medicine, M.D.
- 2014.3-2018.2 Seoul National University, College of Medicine, Ph.D.

• Professional Experience:

- 2011.5-2016.2 **Intern & Residency** in Internal Medicine, Seoul National University Hospital
- 2016.3-2017.2 **Clinical Fellowship** in Hematology & Oncology, Seoul National University Hospital,
- 2017.3-2018.2 **Chief Medical Officer**, Medpacto
- 2018.3-2019.8 **Clinical Assistant Professor**, Seoul National University Hospital, Medical Oncology
- 2019.9-present **Chief Medical Officer**, Lunit Inc. / **Chief Medical Officer**, Bang & Ock Consulting Inc.

• Professional Organizations:

- KSMO
- KCSG
- ASCO
- AACR
- ESMO

• Main Scientific Publications:

1. Ock CY, Hwang JE, Keam B, Kim SB, Shim JJ, Jang HJ, Park S, Sohn BH, Cha M, Ajani JA, Kopetz S, Lee KW, Kim TM, Heo DS, Lee JS. Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers. **Nat Commun** 2017 Oct 19;8(1):1050.
2. Ock CY, Keam B, Kim S, Lee JS, Kim M, Kim TM, Jeon YK, Kim DW, Chung DH, Heo DS. Pan-cancer immunogenomic perspective on the tumor microenvironment based on PD-L1 and CD8 T cell infiltration. **Clin Cancer Res** 2016 May 1;22(9):2261-70.
3. An E*, Ock CY*, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Liao WL, Cecchi F, Blackler A, Thyparambil S, Kim WH, Burrows J, Hembrough T, Catenacci D, Oh DY, Bang YJ. Quantitative proteomic analysis of HER2 expression in the selection of gastric cancer patients for trastuzumab treatment. **Ann Oncol** 2017 Jan 1;28(1):110-115.
4. Ock CY, Lee KW, Kim JW, Kim JS, Kim TY, Lee KH, Han SW, Im SA, Kim TY, Kim WH, Bang YJ, Oh DY. Optimal patient selection for trastuzumab treatment in HER2-positive advanced gastric cancer. **Clin Cancer Res** 2015 Jun 1;21(11):2520-9.
5. Park C, Jeong K, Park JH, Jung S, Bae JM, Kim K*, Ock CY*, Kim M, Keam B, Kim TM, Jeon YK, Lee SH, Lee JS, Kim DW, Kang GH, Chung DH, Heo DS. Pan-cancer methylation analysis reveals an

inverse correlation of tumor immunogenicity with methylation aberrancy. **Cancer Immunol Immunother** 2021 Jun;70(6):1605-1617.

6. Park C, Na KJ, Choi H*, Ock CY*, Ha S, Kim M, Park S, Keam B, Kim TM, Paeng JC, Park IK, Kang CH, Kim DW, Cheon GJ, Kang KW, Kim YT, Heo DS. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma. **Theranostics** 2020 Aug 29;10(23):10838-10848.